The FDA Just Approved a New Once-Daily Weight Loss Pill
If you've been waiting for a GLP-1 weight loss option that doesn't involve a needle, the market just got more interesting.
The FDA approved Eli Lilly's new once-daily weight loss pill on April 1, giving consumers a second oral GLP-1 option alongside Novo Nordisk's Wegovy pill, which only hit the market in December. Eli Lilly is selling it under the brand name Foundayo.
The approval covers adults with obesity or those who are overweight with weight-related health conditions. In clinical trials, people who stayed on the highest dose lost an average of about 27 pounds compared to roughly 2 pounds on a placebo. That's a meaningful difference.
What It Costs
For anyone paying out of pocket, Foundayo starts at $149 a month for the lowest dose and goes up to $349 for higher doses. People with insurance that covers weight loss drugs could pay as little as $25 a month with a Lilly savings card.
That puts it in direct competition with Novo Nordisk's Wegovy pill, which runs $299 a month and just launched a subscription plan at the end of March offering monthly prices as low as $249 for a 12-month commitment.
Neither company is backing down in what's becoming a full-blown GLP-1 price war.
Why Pills Matter
Lilly's chief scientific officer made the case pretty clearly — fewer than one in ten people who could benefit from a GLP-1 are actually taking one. Part of that is cost, part of it is insurance coverage gaps, and part of it is that a lot of people simply don't want to inject themselves weekly.
A daily pill changes that calculus. People already take pills every day for blood pressure and cholesterol without much resistance. Treating obesity the same way could open the door for millions of people who've been sitting on the sidelines.
"We're going to change weight maintenance to be something very much like managing cholesterol and blood pressure," said Dan Skovronsky, Lilly's chief scientific and product officer.
The Side Effects
Worth knowing before anyone runs to their doctor — Foundayo comes with a notable list of potential side effects including nausea, constipation, diarrhea, vomiting, stomach pain, headache, fatigue, gas, reflux, and hair loss. Pretty standard for this class of drugs but worth going in informed.
The Bigger Picture
Goldman Sachs projects global anti-obesity drug sales will hit $105 billion by 2030. Eli Lilly and Novo Nordisk are both positioning aggressively for that market. Insurance coverage is still the sticking point — only about half of large employers currently cover GLP-1 drugs for obesity — but competition between two major players tends to push prices down over time.
Wegovy has had over 600,000 prescriptions since its December launch. Foundayo is entering a market that's clearly ready for it.
Curious for more stories that keep you informed and entertained? From the latest headlines to everyday insights, YourLifeBuzz has more to explore. Dive into what’s next.